VeriStrat ® Results Correlate with Survival Outcomes in Kidney Cancer Patients

< p > Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent ®) and erlotinib (Tarceva®), by survival outcomes. < /p > < p > 10/17/2011 < /p >
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news